Skip to Content
MilliporeSigma
All Photos(1)

Documents

Y0000458

Repaglinide for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Repaglinide, (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid, Novonorm, Prandin

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H36N2O4
CAS Number:
135062-02-1
Molecular Weight:
452.59
MDL number:
MFCD00906179
UNSPSC Code:
41116107
PubChem Substance ID:
329830968
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

repaglinide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N3CCCCC3)ccc1C(O)=O

InChI

1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1

InChI key

FAEKWTJYAYMJKF-QHCPKHFHSA-N

Gene Information

human ... ABCC8(6833) , KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Repaglinide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. It represents a new class of insulin secretagogues, structurally unrelated to sulphonylureas, which were developed for the treatment of type 2 diabetes.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1600824

Repaglinide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1600835

Repaglinide Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0000457

Repaglinide, European Pharmacopoeia (EP) Reference Standard

Y0000459

Repaglinide impurity E, European Pharmacopoeia (EP) Reference Standard

1600813

Repaglinide, United States Pharmacopeia (USP) Reference Standard

1600846

Repaglinide Related Compound C, United States Pharmacopeia (USP) Reference Standard

1600868

Repaglinide Related Compound E, United States Pharmacopeia (USP) Reference Standard

PHR3129

Repaglinide Related Compound A, pharmaceutical secondary standard, certified reference material

PHR3131

Repaglinide Related Compound E, pharmaceutical secondary standard, certified reference material

PHR3408

Repaglinide, pharmaceutical secondary standard, certified reference material

Storage Class

11 - Combustible Solids

wgk_germany

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Christina Jarnert et al.
Diabetes & vascular disease research, 9(4), 287-295 (2012-03-02)
Microcirculatory and endothelial dysfunction are signs of cardiovascular engagement in patients with type 2 diabetes. This study tested whether glucose normalisation may reverse this. Thirty-nine T2DM patients (age 61±7 years, 58% females) with signs of mild diastolic dysfunction were randomised
Deaths in trials should always be reported.
Jeppe Schroll
BMJ (Clinical research ed.), 347, f4219-f4219 (2013-07-06)
Qian Xiang et al.
Pharmacology, 89(1-2), 105-110 (2012-03-09)
The aim of this study was to evaluate the pharmacogenetic variability in the disposition of repaglinide in healthy Chinese subjects. A single dose of 2 mg repaglinide was orally administered to 24 healthy Chinese subjects. The serum concentrations of repaglinide
Severe thrombocytopenia due to repaglinide in a patient with type 2 diabetes.
Hisayuki Katsuyama et al.
Diabetes care, 36(3), e36-e36 (2013-02-23)
Karelle Ménochet et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(9), 1744-1756 (2012-06-06)
Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation. The uptake kinetics of seven organic anion-transporting polypeptide substrates was investigated over a concentration range in plated cryopreserved
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service